National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.

Rapid Review

Commenced Completed Outcome
14/12/2011 06/01/2012 Full Pharmacoeconomic Evaluation not Recommended